456 related articles for article (PubMed ID: 32590316)
1. Mechanisms of immune escape in the cancer immune cycle.
Tang S; Ning Q; Yang L; Mo Z; Tang S
Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
[TBL] [Abstract][Full Text] [Related]
2. CCL21 Programs Immune Activity in Tumor Microenvironment.
Sharma S; Kadam P; Dubinett S
Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
[TBL] [Abstract][Full Text] [Related]
3. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
Front Immunol; 2020; 11():564499. PubMed ID: 33133075
[TBL] [Abstract][Full Text] [Related]
4. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Spranger S
Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
[TBL] [Abstract][Full Text] [Related]
6. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette M; Marabelle A; Houot R
Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
[TBL] [Abstract][Full Text] [Related]
7. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review.
Seliger B
Front Immunol; 2019; 10():2043. PubMed ID: 31555274
[TBL] [Abstract][Full Text] [Related]
9. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
10. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
Yang L; Li A; Lei Q; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
[TBL] [Abstract][Full Text] [Related]
11. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
13. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
14. Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.
Lemasson Q; Akil H; Feuillard J; Vincent-Fabert C
Front Immunol; 2021; 12():669964. PubMed ID: 34113345
[TBL] [Abstract][Full Text] [Related]
15. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
Chouaib S
Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
[TBL] [Abstract][Full Text] [Related]
16. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
Li J; Stanger BZ
Cancer Res; 2020 Oct; 80(19):4037-4041. PubMed ID: 32554552
[TBL] [Abstract][Full Text] [Related]
17. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
Kalantari Khandani N; Ghahremanloo A; Hashemy SI
J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment.
Huang Y; Wang HC; Zhao J; Wu MH; Shih TC
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680031
[TBL] [Abstract][Full Text] [Related]
19. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
Malmberg KJ
Cancer Immunol Immunother; 2004 Oct; 53(10):879-92. PubMed ID: 15338206
[TBL] [Abstract][Full Text] [Related]
20. [Cancer immunotherapy. Importance of overcoming immune suppression].
Malvicini M; Puchulo G; Matar P; Mazzolini G
Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]